<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368806</url>
  </required_header>
  <id_info>
    <org_study_id>JS-OAP3-US01</org_study_id>
    <nct_id>NCT04368806</nct_id>
  </id_info>
  <brief_title>A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis</brief_title>
  <official_title>A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in Patients Diagnosed as Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nature Cell Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nature Cell Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, randomized, placebo controlled, multi-center, superiority study&#xD;
      to evaluate the efficacy and safety of JointStem, autologous adipose tissue derived&#xD;
      mesenchymal stem cells (AdMSC), in patients diagnosed as knee osteoarthritis. Following a&#xD;
      2-week screening period, approximately 140 subjects will be randomly assigned into one of the&#xD;
      following two arms in a 1:1 ratio (1 JointStem : 1 Placebo). After each subject completes&#xD;
      48-Weeks visit (Visit 8) and the data management team confirms all individual data have no&#xD;
      issue, the individual database will be locked and the blinding will be open for the&#xD;
      statistical analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:&#xD;
&#xD;
        -  Visit 1 (Week -7) - Screening&#xD;
&#xD;
        -  Visit 2 (Week -5) - Baseline and Randomization (Lipoaspiration)&#xD;
&#xD;
        -  Visit 3 (Week 0) - Treatment (Intra-articular injection)&#xD;
&#xD;
        -  Visit 4 (Week 4) - 4 weeks follow-up&#xD;
&#xD;
        -  Visit 5 (Week 12) - 12 weeks follow-up&#xD;
&#xD;
        -  Visit 6 (Week 24) - 24 weeks follow-up&#xD;
&#xD;
        -  Visit 7 (Week 36) - 36 weeks follow-up&#xD;
&#xD;
        -  Visit 8 (Week 48) - 48 weeks follow-up (End of Study)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index (WOMAC) function Score</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in WOMAC function score at Week 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) score</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline on Visual Analog Scale (VAS) score at Week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Function)</measure>
    <time_frame>Week 12, 24 and 36</time_frame>
    <description>Change from baseline in WOMAC subscale (Function) score at Week 12, 24, and 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Pain)</measure>
    <time_frame>Week 12, 24, 36, and 48</time_frame>
    <description>Change from baseline in WOMAC subscale (Pain) score at Week 12, 24, 36, and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score</measure>
    <time_frame>Week 12, 24, 36, and 48</time_frame>
    <description>Change from baseline in total WOMAC score at Week 12, 24, 36, and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) score</measure>
    <time_frame>Week 12, 24 and 36</time_frame>
    <description>Change from baseline in VAS score at Week 12, 24 and 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee (IKDC) score</measure>
    <time_frame>Week 12, 24, 36, and 48</time_frame>
    <description>Change from baseline in IKDC score at Week 12, 24, 36, and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form health survey questionnaires (SF-36) score</measure>
    <time_frame>Week12, 24, 36, and 48</time_frame>
    <description>Change from baseline in SF-36 score at Week 12, 24, 36, and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural changes in knee joint</measure>
    <time_frame>Week 48</time_frame>
    <description>Change from baseline in structural changes to the knee joint determined by MRI at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kellgren-Lawrence grade</measure>
    <time_frame>Week 48</time_frame>
    <description>Change from baseline in Kellgren-Lawrence grade of knee osteoarthritis determined by X-ray at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and amount of rescue medication use</measure>
    <time_frame>Week 12, 24, 36, and 48</time_frame>
    <description>The number and amount of rescue medication use at Week 12, 24, 36, and 48</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>JointStem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline with Autologous Serum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JointStem</intervention_name>
    <description>Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)</description>
    <arm_group_label>JointStem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>Normal Saline with autologous Serum</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject who had osteoarthritis of knee diagnosed (according to the clinical and&#xD;
             American College of Rheumatology Criteria)&#xD;
&#xD;
          -  Subject who has ≥ 34 on WOMAC function score at Screening and Baseline&#xD;
&#xD;
          -  Subject who has knee pain ≥ 50 mm out of 100 mm on VAS (Visual Analog Scale) at&#xD;
             Screening and Baseline&#xD;
&#xD;
          -  Subject who has radiographic evidence of grade 3 osteoarthritis in one knee and grade&#xD;
             1 or 2 in the other knee based on the Kellgren and Lawrence radiographic criteria.&#xD;
&#xD;
          -  Subjects whose knee pain persists for at least 12 weeks (about 3 months) prior to&#xD;
             screening and does not improve symptoms with non-operative treatment options&#xD;
&#xD;
          -  Subject who is willing to discontinue all pain medications for osteoarthritis except&#xD;
             rescue medication (&lt; acetaminophen 3.25 g per day) at least 72 hours prior to&#xD;
             screening and throughout the duration of study&#xD;
&#xD;
          -  Subject who is willing and able to give written informed consent for participation in&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who has Body Mass Index (BMI) &gt; 35 kg/m2&#xD;
&#xD;
          -  Subject who has any of following clinically significant disease or has a medical&#xD;
             history of past&#xD;
&#xD;
          -  Uncontrolled comorbid disease under treatment&#xD;
&#xD;
          -  Kidney diseases (glomerulonephritis, chronic renal failure, etc.)&#xD;
&#xD;
          -  Liver diseases (acute and chronic liver diseases including fatty liver, liver&#xD;
             cirrhosis, etc.)&#xD;
&#xD;
          -  Endocrine diseases (hypothyroidism/hyperthyroidism, thyroiditis, diabetes insipidus,&#xD;
             Cushing's disease, etc.)&#xD;
&#xD;
          -  Subject who has any of following clinically significant disease&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Paget's disease, ochronosis, acromegaly, hemochromatosis, or Wilson's disease&#xD;
&#xD;
          -  Genetic diseases (hyperkinesia, collagen gene abnormality, etc.)&#xD;
&#xD;
          -  Inflammatory joint disorders (e.g. rheumatoid inflammation)&#xD;
&#xD;
          -  Infectious joint disorders (e.g. septic arthritis)&#xD;
&#xD;
          -  Other joint disorders (e.g. gout, recurrent pseudogout, articular fracture, primary&#xD;
             osteochondrosis, villonodular synovitis)&#xD;
&#xD;
          -  Subject who has a history of cancer or is diagnosed with cancer and currently&#xD;
             receiving cancer treatment&#xD;
&#xD;
          -  Subject who is positive in pathogenic test (HIV, viral hepatitis, or syphilis)&#xD;
&#xD;
          -  Subject who has heart diseases (myocardial infarction, coronary artery bypass graft&#xD;
             surgery, arrhythmia, or other serious heart diseases) or has history of heart diseases&#xD;
             within 6 months prior to Screening&#xD;
&#xD;
          -  Subject who have received any intra-articular therapy in any joint within 6 months&#xD;
             prior to Screening, or surgery on the relevant knee including articular endoscopic&#xD;
             procedures within 6 months prior to Screening&#xD;
&#xD;
          -  Subject who has history of prolotherapy, or platelet rich plasma injection within 6&#xD;
             months prior to Screening&#xD;
&#xD;
          -  Subject who have received long-acting hyaluronic acid injection (e.g. Synvisc-One®,&#xD;
             etc.) within 12 months prior to Screening&#xD;
&#xD;
          -  Subject who has history of stem cell therapy&#xD;
&#xD;
          -  Subject who have significant lab abnormalities for the following parameters (If the&#xD;
             value is within 10% of the listed laboratory exclusion criterion value and the value&#xD;
             is considered not to be clinically significant by the investigator, the subject can be&#xD;
             considered for enrollment):&#xD;
&#xD;
               -  Serum ALT and AST &gt; 2 x upper limit of normal&#xD;
&#xD;
               -  Serum creatinine out of normal range&#xD;
&#xD;
               -  PT/INR out of normal range&#xD;
&#xD;
               -  Hemoglobin &lt; 10 g/dL for female subject and hemoglobin &lt; 11 g/dL for male subject&#xD;
&#xD;
               -  Platelets out of normal range&#xD;
&#xD;
          -  Subject for whom the investigator judges the lipoaspiration can cause any problem&#xD;
&#xD;
          -  Subject who has history of local anesthetic allergy&#xD;
&#xD;
          -  Subject who has taken anti-inflammatory drugs (prescription and non-prescription&#xD;
             NSAIDs), symptomatic slow acting drugs (glucosamine, chondroitin sulfate, diacerhein&#xD;
             etc.), or oral steroids (prednisone etc.) within 14 days prior to Screening (however,&#xD;
             those who undergo a 14-day wash-out period can participate.)&#xD;
&#xD;
          -  Subject who is an active drug/alcohol abuser&#xD;
&#xD;
          -  Pregnant or breast-feeding women, or women or men who are not using appropriate method&#xD;
             of contraception (appropriate method includes hormones, bilateral tubal ligation, and&#xD;
             barrier method with spermicide, and intra-uterine device for women and vasectomy and&#xD;
             barrier method with spermicide for men; subjects should agree to use appropriate&#xD;
             method)&#xD;
&#xD;
          -  Subject who is enrolled in any other clinical trials within 3 months from Screening&#xD;
&#xD;
          -  Subject who the principal investigator considers inappropriate for the study due to&#xD;
             any other reasons than those listed above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hugh Lee</last_name>
    <phone>301-540-2600</phone>
    <email>hughlee@kcrnresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Lee</last_name>
    <phone>301-540-2600</phone>
    <email>christinelee@kcrnresearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>TriWest Research Associates</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis J. Levy Jr., M.D.</last_name>
      <phone>619-334-4735</phone>
      <email>llevy@triwestresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>David C. Ruiz, Phlebotomist</last_name>
      <phone>619-334-4735</phone>
      <email>dcampos@triwestresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>BioSolutions Clinical Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter B. Hanson, M.D.</last_name>
      <phone>619-637-0770</phone>
      <email>drhanson@biosolutionresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Packard, L.V.N.</last_name>
      <phone>619-637-0770</phone>
      <email>tamara@biosolutionresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Source Healthcare</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy T. Davis, M.D.</last_name>
      <phone>310-574-2777</phone>
      <email>tdavis@sourcehealthcare.com</email>
    </contact>
    <contact_backup>
      <last_name>Afrida Sara, B.S.</last_name>
      <phone>310-574-2777</phone>
      <email>afridasara@g.ucla.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>International Spine Pain, and Performance Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehul Desai, M.D., M.P.H.</last_name>
      <phone>202-851-6845</phone>
      <email>drdesai@isppcenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Sidrah Sheikh, B.A.</last_name>
      <phone>202-808-8295</phone>
      <email>ssheikh@isppcenter.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institute</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradford S. Tucker, M.D.</last_name>
      <phone>844-438-1354</phone>
      <email>bradford.tucker@rothmanortho.com</email>
    </contact>
    <contact_backup>
      <last_name>Mitchee K. Freedman, D.O.</last_name>
      <phone>844-438-1354</phone>
      <email>lm5656@comcast.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabrina M. Strickland, M.D.</last_name>
      <phone>212-606-1000</phone>
    </contact>
    <contact_backup>
      <last_name>Connor F. Fletcher</last_name>
      <phone>212-606-1000</phone>
      <email>Cff43@cornell.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

